Stockscreener 앱 받기
56.30
3.32%
1.81
시간 외 거래:
56.30
전일 마감가:
$54.49
열려 있는:
$54.49
하루 거래량:
325.82K
Relative Volume:
0.86
시가총액:
$3.09B
수익:
-
순이익/손실:
$-118.49M
주가수익비율:
-
EPS:
-
순현금흐름:
$-110.57M
1주 성능:
+2.53%
1개월 성능:
+3.34%
6개월 성능:
+3.89%
1년 성능:
+195.07%
1일 변동 폭
$52.37
$57.01
1주일 범위
$50.48
$57.01
52주 변동 폭
$14.19
$72.29
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Apogee Therapeutics to Participate in Upcoming November Investor Conferences - Marketscreener.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(APGE) Investment Analysis and Advice - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Wedbush Reiterates Outperform Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Unveils Promising Phase 1 Trial Results - TipRanks
Apogee Therapeutics Announces Results Up to 9 Months from - GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel - The Bakersfield Californian
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - StockTitan
Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1%Here's What Happened - MarketBeat
(APGE) Technical Pivots with Risk Controls - Stock Traders Daily
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewswire
11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Down 11.7% in September - MarketBeat
Millennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Analyzing Apogee Therapeutics Inc. (APGE) After Recent Trading Activity - Knox Daily
Ratio Examination: Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now - Insider Monkey
Squarepoint Ops LLC Purchases 25,829 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Inc CEO Michael Henderson Sells 40,000 Shares - GuruFocus.com
Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics CEO sells over $2.2 million in company stock By Investing.com - Investing.com Canada
Apogee Therapeutics executive sells over $370k in company stock By Investing.com - Investing.com Australia
Apogee Therapeutics executive sells over $370k in company stock - Investing.com
Apogee Therapeutics CEO sells over $2.2 million in company stock - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Shares Down 3.7%Here's Why - MarketBeat
Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc - Yahoo Finance
Apogee Therapeutics Inc. [APGE] Records 50-Day SMA of $49.35 - Knox Daily
Ratio Review: Analyzing Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
SVP, Chief Legal Officer Hadas Nicole R. sale 12,016 shares of Akebia Therapeutics Inc. [AKBA] - Knox Daily
10 Best Hot Stocks To Buy Right Now - Insider Monkey
Are Apogee Therapeutics Inc. (APGE) shares a good deal now? - US Post News
Marshall Wace LLP Purchases Shares of 81,946 Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Guggenheim bullish on Apogee stock citing $50B Th2 disease market By Investing.com - Investing.com South Africa
Guggenheim bullish on Apogee stock citing $50B Th2 disease market - Investing.com India
Perceptive Advisors LLC Boosts Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Driehaus Capital Management LLC Buys 54,107 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Renaissance Technologies LLC Has $6.15 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Point72 DIFC Ltd Takes $660,000 Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Down to $59.92 - Defense World
Affinity Asset Advisors LLC Raises Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Long Term Trading Analysis for (APGE) - Stock Traders Daily
Is Apogee Therapeutics Inc. (APGE) worth investing in despite its undervalued state? - US Post News
Integral Health Asset Management LLC Has $3.15 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
History of violence at Atlanta apartment complex where man, woman found shot to death: Records - 11Alive.com WXIA
HighVista Strategies LLC Has $3.11 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Atlanta Community Shaken by Double Homicide on Hollywood Road NW, Police Investigate Shooting - Hoodline
APGE’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
2 people dead after shooting at northwest Atlanta apartment complex - WSB Atlanta
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.11%
0.50%
자본화:
|
볼륨(24시간):